# Belimumab in Patients with Chronic Lymphocytic Leukemia

> **NCT05069051** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Lymphoid Leukemia in Relapse

## Interventions

- **DRUG:** Belimumab 200 MG/ML [Benlysta]
- **DRUG:** standard of care

## Key facts

- **NCT ID:** NCT05069051
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-19
- **Primary completion:** 2026-07-15
- **Final completion:** 2027-07-14
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05069051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05069051, "Belimumab in Patients with Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05069051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*